Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as sevelamer hydrochloride, sevelamer carbonate, Sevelamer hydrochloride, Sevelamer, Sevelamer hydrochloride (Renagel®), Sevelamer Hydrochloride (Renagel®)
sevelamer, sevelamer carbonate · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Sevelamer Hydrochloride (Renagel®) | EXPERIMENTAL | - |
| Calcium acetate (PhosLo® ) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Sevelamer Hydrochloride (Renagel®) | DRUG | Sevelamer hydrochloride three times per day with each meal |
| Calcium acetate (PhosLo® ) | DRUG | Calcium acetate three times per day with each meal |
| Sevelamer hydrochloride | DRUG | - |
Inclusion Criteria: * Willing and able to sign an informed consent form. * Men or women aged 18 years of age or older. * A diagnosis of Chronic Kidney Disease (CKD) and receiving peritoneal dialysis (Continuous cyclical peritoneal dialysis (CAPD), Automated peritoneal dialysis (APD) or Continuous c...
Sevelamer is used in chronic kidney disease, including patients on peritoneal dialysis. It is a small molecule phosphate binder studied for managing elevated phosphate levels in people whose kidneys cannot adequately remove phosphate from the blood. Clinical research has evaluated it in adults aged 18 years and older.
Sanofi develops sevelamer, and the company trades under the ticker SNY. Sanofi's sevelamer hydrochloride product is marketed under the brand name Renagel. The clinical program includes studies conducted across the United States and several European countries, including Belgium, Denmark, France, Italy, the Netherlands, Spain, and the United Kingdom.
Yes, Renagel is a brand name for sevelamer hydrochloride. Sevelamer is also formulated as sevelamer carbonate, a related salt form. Both names refer to the same active ingredient, sevelamer, and searches for sevelamer hydrochloride, sevelamer carbonate, or Renagel all point to this drug.
Sevelamer has been studied in completed trials including NCT00324376, a Phase 2 study comparing once daily with three times daily sevelamer dosing in chronic kidney disease, and NCT00196755, a Phase 3 study of Renagel compared with calcium acetate in peritoneal dialysis patients. Both trials are completed.
Sevelamer has been evaluated in Phase 2 and Phase 3 clinical development. The Phase 2 trial NCT00324376 enrolled 24 participants, and the Phase 3 trial NCT00196755 enrolled 138 participants with peritoneal dialysis and chronic kidney disease. Both studies are listed as completed.
The sevelamer clinical program includes one completed Phase 2 trial with 24 participants and one completed Phase 3 trial with 138 participants, for a total enrollment of 162 across the two studies. Participants were adults aged 18 years and older, and both sexes were eligible.